Drug
Atezolizumab clinical trials
Also written Tecentriq, MPDL3280A and RO5541267.
Keep track of what changes. Save the atezolizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
519 studies that test it; most in 2021 (72); 2 more planned to start later
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 5 |
| 2014 | 6 |
| 2015 | 27 |
| 2016 | 32 |
| 2017 | 56 |
| 2018 | 59 |
| 2019 | 54 |
| 2020 | 66 |
| 2021 | 72 |
| 2022 | 37 |
| 2023 | 50 |
| 2024 | 20 |
| 2025 | 16 |
| 2026 | 18 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 11
Who runs them
Industry 191 · Other 330
Hoffmann-La Roche (115) · National Cancer Institute (NCI) (34) · M.D. Anderson Cancer Center (17) · Genentech, Inc. (17) · The Netherlands Cancer Institute (7) · Memorial Sloan Kettering Cancer Center (6) · Exelixis (5) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (4)
Often tested with
Tested in the same studies.
Bevacizumab (99) · Tiragolumab (34) · Carboplatin (33) · Cobimetinib (29) · Paclitaxel (26) · Vemurafenib (17) · Pembrolizumab (17) · Ipatasertib (17)
Studies
Open first, then newest update. How each study uses atezolizumab is read from its arms, and is right about nine times in ten.
Testing it · 521
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the LungRecruitingPhase 2/3National Cancer Institute (NCI)NCT05058651Written as Atezolizumab
- Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialRecruitingPhase 3National Cancer Institute (NCI)NCT07388524Written as Atezolizumab
- Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingPhase 2Christine RyanNCT06043674Written as Atezolizumab
- PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver CancerRecruitingPhase 2Samsung Medical CenterNCT07884877Written as Immune checkpoint inhibitor-based therapy
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07227597Written as Atezolizumab
- The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)RecruitingPhase 2Inova Health Care ServicesNCT06789757Written as Atezolizumab
- A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingRecruitingPhase 1National Cancer Institute (NCI)NCT06066138Written as Atezolizumab
- Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...RecruitingPhase 2National Cancer Institute (NCI)NCT06161532Written as Atezolizumab
- BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)RecruitingPhase 3SystImmune Inc.NCT07625644Written as BL-M14D1 and Atezolizumab
- Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)RecruitingPhase 2Mark BernardNCT07770100Written as Atezolizumab
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 2Genentech, Inc.NCT04302025Written as Atezolizumab
- SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung CancerRecruitingPhase 2University of WashingtonNCT07322341Written as Atezolizumab
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 1Hoffmann-La RocheNCT04929223Written as Atezolizumab
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Atezolizumab
- Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan CriteriaEnrolling by invitationPhase 4The Methodist Hospital Research InstituteNCT05185505Written as Atezolizumab
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as Atezolizumab
- Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT05019703Written as Atezolizumab
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerRecruitingPhase 1/2Mayo ClinicNCT03942328Written as Atezolizumab
- Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05333458Written as Atezolizumab
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 3Hoffmann-La RocheNCT05862285Written as Atezolizumab
See all 521 studies that test atezolizumab →
Given in every arm · 155 — atezolizumab is usual care beside what is tested
- A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular CarcinomaRecruitingPhase 1/2Tvardi Therapeutics, IncorporatedNCT05440708Written as Atezolizumab
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyRecruitingPhase 3Boehringer IngelheimNCT07472517Written as atezolizumab
- A Study of ZL-1310 in Subjects With Small Cell Lung CancerRecruitingPhase 1Zai Lab (Shanghai) Co., Ltd.NCT06179069Written as Atezolizumab
- Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsRecruitingPhase 3InSightecNCT05317858Written as Atezolizumab
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerRecruitingPhase 2AbbVieNCT07155174Written as Atezolizumab
- A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)RecruitingPhase 1/2Daiichi SankyoNCT06362252Written as Atezolizumab
- DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine CancersNot yet recruitingPhase 1/2Boehringer IngelheimNCT07707895Written as Atezolizumab
- Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingPhase 1/2West China HospitalNCT07835737Written as Atezolizumab & Bevacizumab
- Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT06287775Written as Atezolizumab
- A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid TumorsRecruitingPhase 1/2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07407933Written as Atezolizumab
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialRecruitingPhase 3NRG OncologyNCT07166406Written as Atezolizumab
- A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid TumorsRecruitingPhase 1Chugai PharmaceuticalNCT05907980Written as Atezolizumab
- Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingPhase 1M.D. Anderson Cancer CenterNCT05092373Written as Atezolizumab
- A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)RecruitingPhase 1/2Phanes TherapeuticsNCT05652686Written as Atezolizumab
- Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical ProstatectomyRecruitingPhase 2David OhNCT03821246Written as Atezolizumab
- Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)RecruitingPhase 2/3Tuen Mun HospitalNCT07293468Written as Atezolizumab & Bevacizumab
- Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCCRecruitingPhase 2Replimune, Inc.NCT05733598Written as Atezolizumab
- Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular CarcinomaRecruitingPhase 2Centre Hospitalier Universitaire de BesanconNCT05528952Written as Atezolizumab
- Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 TrialRecruitingPhase 2Centre Hospitalier Universitaire VaudoisNCT07263438Written as Cohort 1: Atezolizumab
- Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung CancerRecruitingPhase 2Roswell Park Cancer InstituteNCT04696575Written as Atezolizumab
Showing 20 of 155.
As the comparator · 17 — what is tested is compared with atezolizumab
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruitingPhase 3Boehringer IngelheimNCT07195695Written as Atezolizumab
- Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerRecruitingPhase 3BioNTech SENCT06712355Written as Atezolizumab
- A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).RecruitingPhase 3Bristol-Myers SquibbNCT06646276Written as Atezolizumab
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaRecruitingPhase 3AstraZenecaNCT06921785Written as Atezolizumab
- Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung CancerRecruitingPhase 2/3PfizerNCT07226999Written as Atezolizumab
- A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine CarcinomaRecruitingPhase 1/2Nanjing Leads Biolabs Co.,LtdNCT06157827Written as Atezolizumab injection
- SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein ThrombosisRecruitingPhase 2Chinese University of Hong KongNCT06823375Written as Atezolizumab plus Bevacizumab
- Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedRecruitingPhase 3Intergroupe Francophone de Cancerologie ThoraciqueNCT06908993Written as Atezolizumab
- Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular InvasionRecruitingPhase 2Asan Medical CenterNCT05992220Written as Atezolizumab plus bevacizumab
- A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCCNot yet recruitingPhase 1/2Biotheus Inc.NCT06584071Written as atezolizumab
- A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2/3AbbVieNCT06109272Written as Atezolizumab
- A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerActive, not recruitingPhase 2Hoffmann-La RocheNCT05645692Written as Atezolizumab
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedPhase 3ImmunityBio, Inc.NCT03520686Written as Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab
- Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast CancerActive, not recruitingPhase 2National Cancer Center, KoreaNCT03756298Written as Atezolizumab
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingPhase 3Jia FanNCT04649489Written as Atezolizumab & Bevacizumab
- Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05224141Written as Atezolizumab
- A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and NeckTerminatedPhase 3Hoffmann-La RocheNCT03452137Written as Atezolizumab
Codes
What other systems call atezolizumab · ClinicalTrials.gg INT000150
- MeSH (NLM) C000594389atezolizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 52CMI0WC3YATEZOLIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1792776Confirmed FDA, Wikidata
- Wikidata Q20707748atezolizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C106250AtezolizumabOne source FDA
- DrugBank DB11595One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000594389 | atezolizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 52CMI0WC3Y | ATEZOLIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1792776 | — | Confirmed FDA, Wikidata |
| Wikidata | Q20707748 | atezolizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C106250 | Atezolizumab | One source FDA |
| DrugBank | DB11595 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.